Blockbuster

Lilly angles for arthritis blockbuster
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis—a market poised to grow to $80 billion by 2020. Lilly submitted ... [...]
3
Like
Save
Sanofi Drug Beats AbbVie's Blockbuster Humira in Clinical Trial
Sanofi and Regeneron Pharmaceuticals Inc. said an experimental rheumatoid arthritis therapy helped patients more than AbbVie Inc.'s Humira in a late-stage trial. The treatment, sarilumab, improved signs and symptoms of rheumatoid arthritis more than ... [...]
6
Like
Save
Sanofi and Regeneron's would-be blockbuster tops Humira in arthritis
The treatment, sarilumab, is an antibody targeting the inflammation-related protein interleukin-6 to treat autoimmune disease. In a late-stage trial enrolling 369 patients, the therapy beat out Humira in clearing up rheumatoid arthritis symptoms after ... [...]
2
Like
Save
Sanofi Drug Beats AbbVie's Blockbuster Humira in Human Trial
Sanofi and Regeneron Pharmaceuticals Inc. said an experimental rheumatoid arthritis therapy helped patients more than AbbVie Inc.'s Humira in a late-stage trial. The treatment, sarilumab, improved signs and symptoms of rheumatoid arthritis more than ... [...]
2
Like
Save
Novartis' Cosentyx to Achieve Blockbuster Sales
The FDA's recent approval of Novartis' Cosentyx for the treatment of adults with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA), will propel the drug to blockbuster status, as it now has three approved indications in the US and Europe ... [...]
5
Like
Save